{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:57:31Z","timestamp":1791910651101,"version":"4.3.4"},"reference-count":130,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.annonc.2024.10.006","type":"journal-article","created":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T10:41:22Z","timestamp":1728988882000},"page":"1088-1104","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":52,"title":["Lung cancer research and treatment: global perspectives and strategic calls to action"],"prefix":"10.1016","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2091-9578","authenticated-orcid":false,"given":"M.-L.","family":"Meyer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.S.","family":"Mok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3964-1492","authenticated-orcid":false,"given":"S.","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.-C.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Aggarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2443-8395","authenticated-orcid":false,"given":"J.","family":"Brahmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Dziadziuszko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Felip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Ferris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.M.","family":"Forde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Gray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Gros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Halmos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Herbst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7821-4928","authenticated-orcid":false,"given":"P.A.","family":"J\u00e4nne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5252-3677","authenticated-orcid":false,"given":"B.E.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.B.","family":"Leighl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Lowy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.U.","family":"Marron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Paz-Ares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Rizvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.M.","family":"Rudin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Shum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Stahel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Trunova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.A.","family":"Bunn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6885-1894","authenticated-orcid":false,"given":"F.R.","family":"Hirsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.annonc.2024.10.006_bib3","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"issue":"7955","key":"10.1016\/j.annonc.2024.10.006_bib4","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/s41586-023-05874-3","article-title":"Lung adenocarcinoma promotion by air pollutants","volume":"616","author":"Hill","year":"2023","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.annonc.2024.10.006_bib5","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/j.annonc.2021.08.1994","article-title":"Early and locally advanced non-small-cell lung cancer: an update of the ESMO Clinical Practice Guidelines focusing on diagnosis, staging, systemic and local therapy","volume":"32","author":"Remon","year":"2021","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.annonc.2024.10.006_bib6","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.annonc.2021.03.207","article-title":"Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Dingemans","year":"2021","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.annonc.2024.10.006_bib7","doi-asserted-by":"crossref","first-page":"e691","DOI":"10.1016\/S2468-2667(23)00131-7","article-title":"Association between duration of smoking abstinence before non-small-cell lung cancer diagnosis and survival: a retrospective, pooled analysis of cohort studies","volume":"8","author":"Fares","year":"2023","journal-title":"Lancet Public Health"},{"issue":"12","key":"10.1016\/j.annonc.2024.10.006_bib8","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.annonc.2024.10.006_bib9","doi-asserted-by":"crossref","first-page":"e427","DOI":"10.1016\/j.chest.2021.06.063","article-title":"Screening for lung cancer: CHEST Guideline and Expert Panel Report","volume":"160","author":"Mazzone","year":"2021","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.annonc.2024.10.006_bib12","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.0787","article-title":"Evaluation of lung cancer risk among persons undergoing screening or guideline-concordant monitoring of lung nodules in the Mississippi Delta","volume":"6","author":"Osarogiagbon","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"2","key":"10.1016\/j.annonc.2024.10.006_bib13","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S2213-2600(23)00338-7","article-title":"Low-dose CT screening among never-smokers with or without a family history of lung cancer in Taiwan: a prospective cohort study","volume":"12","author":"Chang","year":"2024","journal-title":"Lancet Respir Med"},{"issue":"3","key":"10.1016\/j.annonc.2024.10.006_bib14","doi-asserted-by":"crossref","first-page":"320","DOI":"10.7326\/M22-2216","article-title":"Risk model-based lung cancer screening: a cost-effectiveness analysis","volume":"176","author":"Toumazis","year":"2023","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.annonc.2024.10.006_bib15","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1164\/rccm.202204-0727OC","article-title":"Risk-stratified approach for never- and ever-smokers in lung cancer screening: a prospective cohort study in China","volume":"207","author":"Wang","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"issue":"suppl 16","key":"10.1016\/j.annonc.2024.10.006_bib16","doi-asserted-by":"crossref","first-page":"8009","DOI":"10.1200\/JCO.2024.42.16_suppl.8009","article-title":"Taiwan national lung cancer early detection program for heavy smokers and non-smokers with family history of lung cancer","volume":"42","author":"Yang","year":"2024","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"10.1016\/j.annonc.2024.10.006_bib17","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1200\/JCO.22.01345","article-title":"Sybil: a validated deep learning model to predict future lung cancer risk from a single low-dose chest computed tomography","volume":"41","author":"Mikhael","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.annonc.2024.10.006_bib19","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1148\/radiol.2018180212","article-title":"Barriers to lung cancer screening engagement from the patient and provider perspective","volume":"290","author":"Wang","year":"2019","journal-title":"Radiology"},{"issue":"3","key":"10.1016\/j.annonc.2024.10.006_bib20","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.chest.2023.10.028","article-title":"ACR lung-RADS v2022: assessment categories and management recommendations","volume":"165","author":"Christensen","year":"2024","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.annonc.2024.10.006_bib21","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jtho.2023.07.019","article-title":"Current and future perspectives on computed tomography screening for lung cancer: a roadmap from 2023 to 2027 from the International Association for the Study of Lung Cancer","volume":"19","author":"Lam","year":"2024","journal-title":"J\u00a0Thorac Oncol"},{"issue":"10308","key":"10.1016\/j.annonc.2024.10.006_bib23","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/S0140-6736(21)02098-5","article-title":"Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial","volume":"398","author":"Felip","year":"2021","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.annonc.2024.10.006_bib24","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(22)00518-6","article-title":"Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS\/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial","volume":"23","author":"O\u2019Brien","year":"2022","journal-title":"Lancet Oncol"},{"issue":"21","key":"10.1016\/j.annonc.2024.10.006_bib25","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","article-title":"Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer","volume":"386","author":"Forde","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2024.10.006_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2023.10.050","article-title":"LBA1 CheckMate 77T: phase III study comparing neoadjuvant nivolumab (NIVO) plus chemotherapy (chemo) vs neoadjuvant placebo plus chemo followed by surgery and adjuvant NIVO or placebo for previously untreated, resectable stage II\u2013IIIb NSCLC","volume":"34","author":"Cascone","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2024.10.006_bib27","author":"Heymach"},{"issue":"6","key":"10.1016\/j.annonc.2024.10.006_bib28","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1056\/NEJMoa2302983","article-title":"Perioperative pembrolizumab for early-stage non-small-cell lung cancer","volume":"389","author":"Wakelee","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"suppl 36","key":"10.1016\/j.annonc.2024.10.006_bib29","article-title":"Perioperative toripalimab\u00a0+ platinum-doublet chemotherapy vs chemotherapy in resectable stage II\/III non-small cell lung cancer (NSCLC): interim event-free survival (EFS) analysis of the phase III Neotorch study","volume":"41","author":"Lu","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.annonc.2024.10.006_bib30","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.annonc.2024.01.005","article-title":"VP1-2024: RATIONALE-315: event-free survival (EFS) and overall survival (OS) of neoadjuvant tislelizumab (TIS) plus chemotherapy (CT) with adjuvant TIS in resectable non-small cell lung cancer (NSCLC)","volume":"35","author":"Yue","year":"2024","journal-title":"Ann Oncol"},{"issue":"19","key":"10.1016\/j.annonc.2024.10.006_bib31","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1056\/NEJMoa2311926","article-title":"Perioperative nivolumab in resectable lung cancer","volume":"390","author":"Cascone","year":"2024","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2024.10.006_bib32","doi-asserted-by":"crossref","unstructured":"Forde P. Perioperative vs neoadjuvant nivolumab for resectable NSCLC: patient-level data analysis of CheckMate 77T vs CheckMate 816. Abstract PL02.08. Paper presented at the 2024 IASLC World Conference on Lung Cancer. September 7, 2024; San Diego, CA.","DOI":"10.1016\/j.jtho.2024.09.014"},{"issue":"suppl 17","key":"10.1016\/j.annonc.2024.10.006_bib33","article-title":"Overall survival analysis from the ADAURA trial of adjuvant osimertinib in patients with resected EGFR-mutated (EGFRm) stage IB\u2013IIIA non-small cell lung cancer (NSCLC)","volume":"41","author":"Herbst","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"14","key":"10.1016\/j.annonc.2024.10.006_bib34","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1056\/NEJMoa2310532","article-title":"Alectinib in resected ALK-positive non-small-cell lung cancer","volume":"390","author":"Wu","year":"2024","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.annonc.2024.10.006_bib36","doi-asserted-by":"crossref","first-page":"8435","DOI":"10.1038\/s41467-023-44195-x","article-title":"Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I\u2013III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trial","volume":"14","author":"Altorki","year":"2023","journal-title":"Nat Commun"},{"issue":"7957","key":"10.1016\/j.annonc.2024.10.006_bib39","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/s41586-023-05776-4","article-title":"Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA","volume":"616","author":"Abbosh","year":"2023","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.annonc.2024.10.006_bib40","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.3390\/curroncol30030239","article-title":"Stage III non-small-cell lung cancer: an overview of treatment options","volume":"30","author":"Petrella","year":"2023","journal-title":"Curr Oncol"},{"issue":"6","key":"10.1016\/j.annonc.2024.10.006_bib41","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1056\/NEJMoa2215530","article-title":"Perioperative nivolumab and chemotherapy in stage III non-small-cell lung cancer","volume":"389","author":"Provencio","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.annonc.2024.10.006_bib42","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1200\/JCO.21.01308","article-title":"Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"40","author":"Spigel","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.annonc.2024.10.006_bib43","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1093\/annonc\/mdy553","article-title":"Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP)","volume":"30","author":"Peters","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2024.10.006_bib44","doi-asserted-by":"crossref","unstructured":"Bradley J. Durvalumab in combination with chemoradiotherapy for patients with unresectable stage III NSCLC: final results from PACIFIC-2. Paper presented at the ELCC 2024. March 21, 2024; Prag.","DOI":"10.1016\/j.esmoop.2024.102986"},{"issue":"3","key":"10.1016\/j.annonc.2024.10.006_bib45","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.semradonc.2023.03.003","article-title":"The promise and future of radiomics for personalized radiotherapy dosing and adaptation","volume":"33","author":"Ger","year":"2023","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.annonc.2024.10.006_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.109637","article-title":"CT-based radiomics nomogram may predict who can benefit from adaptive radiotherapy in patients with local advanced-NSCLC patients","volume":"183","author":"Zhou","year":"2023","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.annonc.2024.10.006_bib47","author":"Bristol Myers"},{"issue":"7","key":"10.1016\/j.annonc.2024.10.006_bib48","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1056\/NEJMoa2402614","article-title":"Osimertinib after chemoradiotherapy in stage III EGFR-mutated NSCLC","volume":"391","author":"Lu","year":"2024","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2024.10.006_bib49","unstructured":"Meng X. Abstract PL04.13. Aumolertinib after chemoradiotherapy in unresectable stage III non-small-cell lung cancer with EGFR mutation: interim analysis of the phase III POLESTAR study. Paper presented at the 2024 IASLC World Conference on Lung Cancer. September 7, 2024; San Diego, CA."},{"issue":"6","key":"10.1016\/j.annonc.2024.10.006_bib50","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1200\/JCO.21.01626","article-title":"Targeted therapies for lung cancer patients with oncogenic driver molecular alterations","volume":"40","author":"Tan","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.annonc.2024.10.006_bib51","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0247620","article-title":"Epidemiological and clinical burden of EGFR Exon 20 insertion in advanced non-small cell lung cancer: a systematic literature review","volume":"16","author":"Burnett","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.annonc.2024.10.006_bib52","article-title":"Prognosis and concurrent genomic alterations in patients with advanced NSCLC harboring MET amplification or MET exon 14 skipping mutation treated with MET inhibitor: a retrospective study","volume":"11","author":"Liu","year":"2021","journal-title":"Front Oncol"},{"issue":"7511","key":"10.1016\/j.annonc.2024.10.006_bib53","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nature13385","article-title":"Comprehensive molecular profiling of lung adenocarcinoma","volume":"511","year":"2014","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.annonc.2024.10.006_bib54","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/JTO.0000000000000033","article-title":"A\u00a0prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER)","volume":"9","author":"Shi","year":"2014","journal-title":"J\u00a0Thorac Oncol"},{"issue":"6","key":"10.1016\/j.annonc.2024.10.006_bib55","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1158\/2159-8290.CD-16-1337","article-title":"Prospective comprehensive molecular characterization of lung adenocarcinomas for efficient patient matching to approved and emerging therapies","volume":"7","author":"Jordan","year":"2017","journal-title":"Cancer Discov"},{"issue":"9","key":"10.1016\/j.annonc.2024.10.006_bib56","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1093\/annonc\/mdt205","article-title":"Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap)","volume":"24","author":"Dearden","year":"2013","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.annonc.2024.10.006_bib57","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.annonc.2022.12.009","article-title":"Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Hendriks","year":"2023","journal-title":"Ann Oncol"},{"issue":"21","key":"10.1016\/j.annonc.2024.10.006_bib58","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1056\/NEJMoa2306434","article-title":"Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC","volume":"389","author":"Planchard","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2024.10.006_bib59","series-title":"Paper presented at the ESMO Congress 2023","article-title":"LBA14: Amivantamab plus lazertinib vs osimertinib as first-line treatment in patients with EGFR-mutated, advanced non-small cell lung cancer (NSCLC): primary results from MARIPOSA, a phase III, global, randomized, controlled trial","author":"Cho","year":"2023"},{"issue":"suppl 17","key":"10.1016\/j.annonc.2024.10.006_bib60","article-title":"Pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor (TKI)-resistant, EGFR-mutant, metastatic nonsquamous NSCLC: phase 3 KEYNOTE-789 study","volume":"41","author":"Yang","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"10.1016\/j.annonc.2024.10.006_bib61","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1200\/JCO.23.01017","article-title":"Nivolumab plus chemotherapy in epidermal growth factor receptor-mutated metastatic non-small-cell lung cancer after disease progression on epidermal growth factor receptor tyrosine kinase inhibitors: final results of CheckMate 722","volume":"42","author":"Mok","year":"2024","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"10.1016\/j.annonc.2024.10.006_bib62","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/S2213-2600(23)00135-2","volume":"11","author":"Lu","year":"2023","journal-title":"Lancet Respir Med"},{"issue":"5","key":"10.1016\/j.annonc.2024.10.006_bib63","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S2213-2600(19)30084-0","article-title":"Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial","volume":"7","author":"Reck","year":"2019","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.annonc.2024.10.006_bib64","doi-asserted-by":"crossref","first-page":"S1311","DOI":"10.1016\/j.annonc.2023.10.068","article-title":"LBA67 A phase III, randomized study of atezolizumab plus bevacizumab and chemotherapy in patients with EGFR or ALK mutated in non-small cell lung cancer (ATTLAS, KCSG-LU19-04)","volume":"34","author":"Ahn","year":"2023","journal-title":"Ann Oncol"},{"issue":"suppl 16","key":"10.1016\/j.annonc.2024.10.006_bib65","doi-asserted-by":"crossref","first-page":"8508","DOI":"10.1200\/JCO.2024.42.16_suppl.8508","article-title":"Ivonescimab combined with chemotherapy in patients with EGFR-mutant non-squamous non-small cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor treatment (HARMONi-A): a randomized, double-blind, multi-center, phase 3 trial","volume":"42","author":"Zhang","year":"2024","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"10.1016\/j.annonc.2024.10.006_bib66","doi-asserted-by":"crossref","first-page":"S64","DOI":"10.1016\/j.jtho.2023.09.059","article-title":"OA09.06 IMpower151: phase III study of atezolizumab\u00a0+ bevacizumab\u00a0+ chemotherapy in 1L metastatic nonsquamous NSCLC","volume":"18","author":"Zhou","year":"2023","journal-title":"J\u00a0Thorac Oncol"},{"issue":"2","key":"10.1016\/j.annonc.2024.10.006_bib67","doi-asserted-by":"crossref","first-page":"504","DOI":"10.3390\/cancers15020504","article-title":"Mechanisms of acquired resistance and tolerance to EGFR targeted therapy in non-small cell lung cancer","volume":"15","author":"Chhouri","year":"2023","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.annonc.2024.10.006_bib68","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.annonc.2023.10.117","article-title":"Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study","volume":"35","author":"Passaro","year":"2024","journal-title":"Ann Oncol"},{"issue":"30","key":"10.1016\/j.annonc.2024.10.006_bib69","doi-asserted-by":"crossref","first-page":"3593","DOI":"10.1200\/JCO.24.01001","article-title":"Subcutaneous versus intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated NSCLC: primary results from the phase 3 PALOMA-3 study","volume":"42","author":"Leighl","year":"2024","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2024.10.006_bib70","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2024.104295","article-title":"The study of primary and acquired resistance to first-line osimertinib to improve the outcome of EGFR-mutated advanced non-small cell lung cancer patients: the challenge is open for new therapeutic strategies","volume":"196","author":"Ferro","year":"2024","journal-title":"Crit Rev Oncol Hematol"},{"issue":"suppl 16","key":"10.1016\/j.annonc.2024.10.006_bib71","doi-asserted-by":"crossref","first-page":"9021","DOI":"10.1200\/JCO.2023.41.16_suppl.9021","article-title":"Tepotinib\u00a0+ osimertinib for EGFR mutant (EGFR m) NSCLC with MET amplification (MET amp) after first-line (1L) osimertinib","volume":"41","author":"Tan","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"22","key":"10.1016\/j.annonc.2024.10.006_bib73","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1056\/NEJMoa2306441","article-title":"Amivantamab plus chemotherapy in NSCLC with EGFR exon 20 insertions","volume":"389","author":"Zhou","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"10454","key":"10.1016\/j.annonc.2024.10.006_bib76","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S0140-6736(24)01029-8","article-title":"New promises and challenges in the treatment of advanced non-small-cell lung cancer","volume":"404","author":"Meyer","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.annonc.2024.10.006_bib77","unstructured":"Planchard D. FURTHER: a global, randomized study of firmonertinib at two dose levels in TKI-naive, advanced NSCLC with EGFR PACC mutations. Paper presented at the 2024 World Conference on Lung Cancer. September 7, 2024; San Diego, CA."},{"key":"10.1016\/j.annonc.2024.10.006_bib78","doi-asserted-by":"crossref","DOI":"10.1177\/17588359231225036","article-title":"Efficacy of immunotherapy in patients with oncogene-driven non-small-cell lung cancer: a systematic review and meta-analysis","volume":"16","author":"Chen","year":"2024","journal-title":"Ther Adv Med Oncol"},{"issue":"10378","key":"10.1016\/j.annonc.2024.10.006_bib79","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S0140-6736(23)00221-0","article-title":"Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial","volume":"401","author":"de Langen","year":"2023","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.annonc.2024.10.006_bib80","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s40164-023-00453-8","article-title":"The current landscape of using direct inhibitors to target KRASG12C-mutated NSCLC","volume":"12","author":"Batrash","year":"2023","journal-title":"Exp Hematol Oncol"},{"issue":"suppl 17","key":"10.1016\/j.annonc.2024.10.006_bib81","article-title":"KRYSTAL-12: phase 3 study of adagrasib versus docetaxel in patients with previously treated advanced\/metastatic non-small cell lung cancer (NSCLC) harboring a KRAS G12C mutation","volume":"42","author":"Mok","year":"2024","journal-title":"J\u00a0Clin Oncol"},{"issue":"25","key":"10.1016\/j.annonc.2024.10.006_bib82","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1056\/NEJMoa2105281","article-title":"Acquired resistance to KRASG12C inhibition in cancer","volume":"384","author":"Awad","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.annonc.2024.10.006_bib83","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1158\/2159-8290.CD-22-1420","article-title":"Comutations and KRASG12C inhibitor efficacy in advanced NSCLC","volume":"13","author":"Negrao","year":"2023","journal-title":"Cancer Discov"},{"issue":"29","key":"10.1016\/j.annonc.2024.10.006_bib84","doi-asserted-by":"crossref","first-page":"3400","DOI":"10.1200\/JCO.24.00581","article-title":"Lorlatinib versus crizotinib in patients with advanced ALK-positive non-small cell lung cancer: 5-year outcomes from the Phase III CROWN study","volume":"42","author":"Solomon","year":"2024","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.annonc.2024.10.006_bib85","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1056\/NEJMoa2302299","article-title":"Repotrectinib in ROS1 Fusion-positive non-small-cell lung cancer","volume":"390","author":"Drilon","year":"2024","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2024.10.006_bib86","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1125547","article-title":"Recent progress in targeted therapy for non-small cell lung cancer","volume":"14","author":"Xiao","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.annonc.2024.10.006_bib87","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2022.216022","article-title":"SMARCA4: Current status and future perspectives in non-small-cell lung cancer","volume":"554","author":"Tian","year":"2023","journal-title":"Cancer Lett"},{"issue":"11","key":"10.1016\/j.annonc.2024.10.006_bib88","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1158\/2159-8290.CD-23-0669","article-title":"MRTX1719 is an MTA-cooperative PRMT5 inhibitor that exhibits synthetic lethality in preclinical models and patients with MTAP-deleted cancer","volume":"13","author":"Engstrom","year":"2023","journal-title":"Cancer Discov"},{"issue":"3","key":"10.1016\/j.annonc.2024.10.006_bib89","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.pccm.2023.07.001","article-title":"Role of c-Myc in lung cancer: progress, challenges, and prospects","volume":"1","author":"Wallbillich","year":"2023","journal-title":"Chin Med J Pulm Crit Care Med"},{"issue":"6","key":"10.1016\/j.annonc.2024.10.006_bib90","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1158\/2159-8290.CD-24-0027","article-title":"Translational and therapeutic evaluation of RAS-GTP inhibition by RMC-6236 in RAS-driven cancers","volume":"14","author":"Jiang","year":"2024","journal-title":"Cancer Discov"},{"issue":"4","key":"10.1016\/j.annonc.2024.10.006_bib91","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.annonc.2022.12.013","article-title":"Non-oncogene addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Hendriks","year":"2023","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.annonc.2024.10.006_bib92","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jtho.2021.10.013","article-title":"Diminished efficacy of programmed death-(ligand)1 inhibition in STK11- and KEAP1-mutant lung adenocarcinoma is affected by KRAS mutation status","volume":"17","author":"Ricciuti","year":"2022","journal-title":"J\u00a0Thorac Oncol"},{"issue":"6","key":"10.1016\/j.annonc.2024.10.006_bib93","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1200\/JCO.22.00975","article-title":"Durvalumab with or without tremelimumab in combination with chemotherapy as first-line therapy for metastatic non-small-cell lung cancer: the phase III POSEIDON study","volume":"41","author":"Johnson","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.annonc.2024.10.006_bib94","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S1470-2045(20)30641-0","article-title":"First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial","volume":"22","author":"Paz-Ares","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2024.10.006_bib95","doi-asserted-by":"crossref","first-page":"S1423","DOI":"10.1016\/j.annonc.2022.08.058","article-title":"LBA56 MEDI5752 or pembrolizumab (P) plus carboplatin\/pemetrexed (CP) in treatment-na\u00efve (1L) non-small cell lung cancer (NSCLC): a phase Ib\/II trial","volume":"33","author":"Ahn","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2024.10.006_bib96","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102545","article-title":"Immunotherapy-based combinations in metastatic NSCLC","volume":"116","author":"Desai","year":"2023","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"10.1016\/j.annonc.2024.10.006_bib98","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.annonc.2023.10.004","article-title":"SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"35","author":"Borghaei","year":"2024","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.annonc.2024.10.006_bib99","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1016\/S1556-0864(23)00260-5","article-title":"60 CONTACT-01: Efficacy and safety from a phase III study of atezolizumab (atezo)\u00a0+ cabozantinib (cabo) vs docetaxel (doc) monotherapy in patients (pts) with metastatic NSCLC (mNSCLC) previously treated with checkpoint inhibitors and chemotherapy","volume":"18","author":"Neal","year":"2023","journal-title":"J\u00a0Thorac Oncol"},{"issue":"11","key":"10.1016\/j.annonc.2024.10.006_bib101","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1200\/JCO.23.00580","article-title":"Genomic and immunophenotypic landscape of acquired resistance to PD-(L)1 blockade in non-small-cell lung cancer","volume":"42","author":"Ricciuti","year":"2024","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.annonc.2024.10.006_bib102","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.jtho.2018.11.034","article-title":"Antibody-drug conjugates for the therapy of thoracic malignancies","volume":"14","author":"Xie","year":"2019","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.annonc.2024.10.006_bib104","article-title":"Antibody-drug conjugates for lung cancer: payloads and progress","volume":"43","author":"Rosner","year":"2023","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"5","key":"10.1016\/j.annonc.2024.10.006_bib105","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1158\/2159-8290.CD-20-0215","article-title":"HER2-mediated internalization of cytotoxic agents in ERBB2 amplified or mutant lung cancers","volume":"10","author":"Li","year":"2020","journal-title":"Cancer Discov"},{"issue":"1","key":"10.1016\/j.annonc.2024.10.006_bib106","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","article-title":"Antibody drug conjugate: the \u201cbiological missile\u201d for targeted cancer therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Sig Transduct Target Ther"},{"key":"10.1016\/j.annonc.2024.10.006_bib107","series-title":"ESMO Congress 2023","article-title":"Datopotamab deruxtecan (Dato-DXd) vs docetaxel in previously treated advanced\/metastatic (adv\/met) non-small cell lung cancer (NSCLC): results of the randomized phase III study TROPION-Lung01","author":"Lisberg","year":"2023"},{"issue":"24","key":"10.1016\/j.annonc.2024.10.006_bib109","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.1200\/JCO.24.00733","article-title":"Sacituzumab govitecan versus docetaxel for previously treated advanced or metastatic non-small cell lung cancer: the randomized, open-label phase III EVOKE-01 study","volume":"42","author":"Paz-Ares","year":"2024","journal-title":"J\u00a0Clin Oncol"},{"issue":"35","key":"10.1016\/j.annonc.2024.10.006_bib110","doi-asserted-by":"crossref","first-page":"5363","DOI":"10.1200\/JCO.23.01476","article-title":"HERTHENA-Lung01, a phase II trial of patritumab deruxtecan (HER3-DXd) in epidermal growth factor receptor-mutated non-small-cell lung cancer after epidermal growth factor receptor tyrosine kinase inhibitor therapy and platinum-based chemotherapy","volume":"41","author":"Yu","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 16","key":"10.1016\/j.annonc.2024.10.006_bib111","doi-asserted-by":"crossref","first-page":"9017","DOI":"10.1200\/JCO.2022.40.16_suppl.9017","article-title":"Efficacy and safety of patritumab deruxtecan (HER3-DXd) in advanced\/metastatic non-small cell lung cancer (NSCLC) without EGFR-activating mutations","volume":"40","author":"Steuer","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"suppl 16","key":"10.1016\/j.annonc.2024.10.006_bib112","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1200\/JCO.2024.42.16_suppl.103","article-title":"Telisotuzumab vedotin monotherapy in patients with previously treated c-Met\u2013overexpressing non-squamous EGFR wildtype advanced NSCLC: primary analysis of the LUMINOSITY trial","volume":"42","author":"Camidge","year":"2024","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.annonc.2024.10.006_bib113","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/s41571-021-00470-8","article-title":"Unlocking the potential of antibody\u2013drug conjugates for cancer therapy","volume":"18","author":"Drago","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"10.1016\/j.annonc.2024.10.006_bib114","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.annonc.2024.02.003","article-title":"Translational insights and overall survival in the U31402-A-U102 study of patritumab deruxtecan (HER3-DXd) in EGFR-mutated NSCLC","volume":"35","author":"Yu","year":"2024","journal-title":"Ann Oncol"},{"issue":"21","key":"10.1016\/j.annonc.2024.10.006_bib115","doi-asserted-by":"crossref","first-page":"3747","DOI":"10.1200\/JCO.23.00013","article-title":"Antibody-drug conjugates in lung cancer: recent advances and implementing strategies","volume":"41","author":"Passaro","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.annonc.2024.10.006_bib116","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1001\/jamaoncol.2022.5631","article-title":"Emerging strategies for the treatment of small cell lung cancer: a review","volume":"9","author":"Petty","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.annonc.2024.10.006_bib117","author":"Spigel"},{"issue":"suppl 2","key":"10.1016\/j.annonc.2024.10.006_bib118","first-page":"A493","article-title":"464 2SMALL (NCT04253145) phase I part: lurbinectidine (LUR) in combination with atezolizumab (ATZ) for second line extensive stage small cell lung cancer (ES-SCLC) patients (pts)","volume":"9","author":"Aix","year":"2021","journal-title":"J\u00a0Immunother Cancer"},{"issue":"suppl 16","key":"10.1016\/j.annonc.2024.10.006_bib119","doi-asserted-by":"crossref","first-page":"8581","DOI":"10.1200\/JCO.2022.40.16_suppl.8581","article-title":"A\u00a0phase 1\/2 trial of lurbinectedin (L) in combination with pembrolizumab (P) in relapsed small cell lung cancer (SCLC): the LUPER study","volume":"40","author":"Calles","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"22","key":"10.1016\/j.annonc.2024.10.006_bib121","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1056\/NEJMoa2307980","article-title":"Tarlatamab for patients with previously treated small-cell lung cancer","volume":"389","author":"Ahn","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.annonc.2024.10.006_bib122","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s13045-023-01464-y","article-title":"Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer","volume":"16","author":"Rudin","year":"2023","journal-title":"J\u00a0Hematol Oncol"},{"issue":"11","key":"10.1016\/j.annonc.2024.10.006_bib123","doi-asserted-by":"crossref","first-page":"S54","DOI":"10.1016\/j.jtho.2023.09.042","article-title":"OA05.05 Ifinatamab deruxtecan (I-DXd; DS-7300) in patients with refractory SCLC: a subgroup analysis of a phase 1\/2 study","volume":"18","author":"Johnson","year":"2023","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.annonc.2024.10.006_bib124","doi-asserted-by":"crossref","first-page":"S1061","DOI":"10.1016\/j.annonc.2023.09.1221","article-title":"1990MO Sacituzumab govitecan (SG) as second-line (2L) treatment for extensive stage small cell lung cancer (ES-SCLC): preliminary results from the phase II TROPiCS-03 basket trial","volume":"34","author":"Dowlati","year":"2023","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2024.10.006_bib125","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1186\/s12967-023-04471-2","article-title":"The current status and future of ADC therapy for small cell lung cancer: a promising approach","volume":"21","author":"Zhou","year":"2023","journal-title":"J\u00a0Transl Med"},{"issue":"suppl 16","key":"10.1016\/j.annonc.2024.10.006_bib126","doi-asserted-by":"crossref","first-page":"3001","DOI":"10.1200\/JCO.2024.42.16_suppl.3001","article-title":"First-in-human study of ABBV-706, a seizure-related homolog protein 6 (SEZ6)\u2013targeting antibody-drug conjugate (ADC), in patients (pts) with advanced solid tumors","volume":"42","author":"Chandana","year":"2024","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.annonc.2024.10.006_bib127","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/s41568-019-0133-9","article-title":"Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data","volume":"19","author":"Rudin","year":"2019","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"10.1016\/j.annonc.2024.10.006_bib128","doi-asserted-by":"crossref","first-page":"620","DOI":"10.3322\/caac.21785","article-title":"Clinical insights into small cell lung cancer: tumor heterogeneity, diagnosis, therapy, and future directions","volume":"73","author":"Megyesfalvi","year":"2023","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"10.1016\/j.annonc.2024.10.006_bib129","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.ccell.2020.12.014","article-title":"Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities","volume":"39","author":"Gay","year":"2021","journal-title":"Cancer Cell"},{"issue":"suppl 16","key":"10.1016\/j.annonc.2024.10.006_bib130","doi-asserted-by":"crossref","first-page":"8503","DOI":"10.1200\/JCO.2023.41.16_suppl.8503","article-title":"Exploratory biomarker analysis of the phase 3 KEYNOTE-604 study of pembrolizumab plus etoposide for extensive-stage SCLC","volume":"41","author":"Rudin","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"23","key":"10.1016\/j.annonc.2024.10.006_bib131","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1200\/JCO.2018.77.7672","article-title":"Randomized, double-blind, phase II study of temozolomide in combination with either veliparib or placebo in patients with relapsed-sensitive or refractory small-cell lung cancer","volume":"36","author":"Pietanza","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"10.1016\/j.annonc.2024.10.006_bib132","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1111\/1759-7714.14375","article-title":"CAR-T cell therapy for lung cancer: potential and perspective","volume":"13","author":"Chen","year":"2022","journal-title":"Thorac Cancer"},{"issue":"14","key":"10.1016\/j.annonc.2024.10.006_bib133","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.3390\/cancers15143733","article-title":"Cellular therapy for lung cancer: focusing on chimeric antigen receptor T (CAR T) cells and tumor-infiltrating lymphocyte (TIL) therapy","volume":"15","author":"Katiyar","year":"2023","journal-title":"Cancers"},{"issue":"suppl 17","key":"10.1016\/j.annonc.2024.10.006_bib134","article-title":"Tumor treating field (TTFields) therapy with standard of care (SOC) in metastatic non-small cell lung cancer (mNSCLC) following platinum failure: randomized, phase 3 LUNAR study","volume":"41","author":"Leal","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.annonc.2024.10.006_bib135","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1200\/JCO.21.01845","article-title":"Managing resistance to immune checkpoint inhibitors in lung cancer: treatment and novel strategies","volume":"40","author":"Passaro","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.annonc.2024.10.006_bib136","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1038\/s41591-021-01462-y","article-title":"Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial","volume":"27","author":"Creelan","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.annonc.2024.10.006_bib137","article-title":"Recent advances in mRNA cancer vaccines: meeting challenges and embracing opportunities","volume":"14","author":"Wang","year":"2023","journal-title":"Front Immunol"},{"issue":"suppl 16","key":"10.1016\/j.annonc.2024.10.006_bib138","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1200\/JCO.2024.42.16_suppl.2008","article-title":"Results from METIS (EF-25), an international, multicenter phase III randomized study evaluating the efficacy and safety of tumor treating fields (TTFields) therapy in NSCLC patients with brain metastases","volume":"42","author":"Mehta","year":"2024","journal-title":"J\u00a0Clin Oncol"},{"issue":"13","key":"10.1016\/j.annonc.2024.10.006_bib139","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241310803","article-title":"Liquid biopsy in NSCLC: an investigation with multiple clinical implications","volume":"24","author":"Bertoli","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"suppl 16","key":"10.1016\/j.annonc.2024.10.006_bib140","doi-asserted-by":"crossref","first-page":"9019","DOI":"10.1200\/JCO.2023.41.16_suppl.9019","article-title":"LIBELULE: a randomized phase III study to evaluate the clinical relevance of early liquid biopsy (LB) in patients with suspicious metastatic lung cancer","volume":"41","author":"Swalduz","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"10.1016\/j.annonc.2024.10.006_bib141","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1158\/2159-8290.CD-17-0716","article-title":"Early detection of molecular residual disease in localized lung cancer by circulating tumor DNA profiling","volume":"7","author":"Chaudhuri","year":"2017","journal-title":"Cancer Discov"},{"issue":"5","key":"10.1016\/j.annonc.2024.10.006_bib142","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.annonc.2022.02.007","article-title":"Residual ctDNA after treatment predicts early relapse in patients with early-stage non-small cell lung cancer","volume":"33","author":"Gale","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2024.10.006_bib144","article-title":"Socioeconomic inequalities in cancer mortality between and within countries in Europe: a population-based study","volume":"25","author":"Vaccarella","year":"2023","journal-title":"Lancet Reg Health Eur"},{"issue":"1","key":"10.1016\/j.annonc.2024.10.006_bib145","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1200\/JOP.2017.025288","article-title":"Representation of minorities and women in oncology clinical trials: review of the past 14 years","volume":"14","author":"Duma","year":"2018","journal-title":"J\u00a0Oncol Pract"},{"issue":"2","key":"10.1016\/j.annonc.2024.10.006_bib146","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0030019","article-title":"Are racial and ethnic minorities less willing to participate in health research?","volume":"3","author":"Wendler","year":"2005","journal-title":"PLoS Med"},{"issue":"19","key":"10.1016\/j.annonc.2024.10.006_bib149","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1200\/JCO.22.00754","article-title":"Increasing racial and ethnic diversity in cancer clinical trials: an American Society of Clinical Oncology and Association of Community Cancer Centers Joint Research Statement","volume":"40","author":"Oyer","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"46","key":"10.1016\/j.annonc.2024.10.006_bib153","first-page":"5","article-title":"S2302 Pragmatica-Lung Trial: reaching more representative groups of patients with exciting clinical trials","volume":"48","author":"Gray","year":"2022","journal-title":"Cancer Lett"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753424040559?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753424040559?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T20:39:57Z","timestamp":1734727197000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753424040559"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":130,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S0923753424040559"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2024.10.006","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lung cancer research and treatment: global perspectives and strategic calls to action","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2024.10.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 European Society for Medical Oncology. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}